110 related articles for article (PubMed ID: 25742233)
1. (18)F-FDOPA accumulation in traumatic rib fractures: a potential pitfall.
Stormezand GN; Glaudemans AW; Slart RH
Clin Nucl Med; 2015 Jun; 40(6):531-2. PubMed ID: 25742233
[TBL] [Abstract][Full Text] [Related]
2. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
3. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDOPA: a multiple-target molecule.
Minn H; Kauhanen S; Seppänen M; Nuutila P
J Nucl Med; 2009 Dec; 50(12):1915-8. PubMed ID: 19910423
[TBL] [Abstract][Full Text] [Related]
6. Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.
Noordzij W; van Beek AP; Tio RA; van der Horst-Schrivers AN; de Vries EG; van Ginkel B; Walenkamp AM; Glaudemans AW; Slart RH; Dierckx RA
PLoS One; 2014; 9(11):e112278. PubMed ID: 25397775
[TBL] [Abstract][Full Text] [Related]
7. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
8. Epiglottic Squamous Cell Carcinoma Showing Unexpected 18F-FDOPA Uptake on PET/CT Investigation.
Dietemann S; Debry C; Onea A; Namer IJ; Imperiale A
Clin Nucl Med; 2015 Jul; 40(7):e370-1. PubMed ID: 26018705
[TBL] [Abstract][Full Text] [Related]
9. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous (18)F-FDOPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis: further step toward a theranostic approach.
Imperiale A; Garnon J; Bachellier P; Gangi A; Namer IJ
Clin Nucl Med; 2015 Jun; 40(6):e334-5. PubMed ID: 25706791
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
12. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY
Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015
[TBL] [Abstract][Full Text] [Related]
13. 3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
Seibyl JP; Chen W; Silverman DH
Semin Nucl Med; 2007 Nov; 37(6):440-50. PubMed ID: 17920351
[TBL] [Abstract][Full Text] [Related]
14. Terminal ileum neuroendocrine incidentaloma in a patient with sporadic medullary thyroid carcinoma: findings from 18F-FDOPA PET/CT investigation.
Imperiale A; Rust E; Boulanger C; Roedlich MN; Ollier JC; Schneegans O
Clin Nucl Med; 2012 Aug; 37(8):e206-8. PubMed ID: 22785529
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
16. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
17. Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on ¹⁸F-FDOPA PET/CT.
Imperiale A; Addeo P; Averous G; Namer IJ; Bachellier P
J Clin Endocrinol Metab; 2013 Jul; 98(7):2643-4. PubMed ID: 23671317
[No Abstract] [Full Text] [Related]
18. Primary Neuroendocrine Tumor in a Horseshoe Kidney With Positive 111In-Pentetreotide Somatostatin Receptor Scintigraphy and Negative 18F-DOPA PET/CT.
Gauthé M; Lièvre A; Alberini JL
Clin Nucl Med; 2015 Nov; 40(11):e516-7. PubMed ID: 26204216
[TBL] [Abstract][Full Text] [Related]
19. Update on nuclear medicine imaging of neuroendocrine tumors.
Goldsmith SJ
Future Oncol; 2009 Feb; 5(1):75-84. PubMed ID: 19243300
[TBL] [Abstract][Full Text] [Related]
20. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]